Company Overview
Personalis, Inc. operates within the healthcare sector, specifically focusing on diagnostics and research, where it develops, markets, and sells advanced cancer genomic tests and services across the United States and international markets. The company's core product offering includes NeXT Personal, a tumor-informed liquid biopsy test designed for the detection of minimal residual disease, therapy response, and recurrence monitoring. In terms of scale, the company currently holds a market capitalization of $797.29M and generates annual revenue of $69.65M based on trailing twelve-month data. With an employee base of 259, the organization maintains a relatively compact workforce to support its specialized genomic testing operations. The market cap figure of $797.29M combined with the annual revenue of $69.65M indicates that the market values the company at a multiple significantly higher than its current revenue generation, reflecting high expectations for future expansion or the strategic importance of its diagnostic technology within the broader genomic medicine landscape.
Financial Health
The company reported a revenue of $69.65M for the trailing twelve months, yet it recorded a net income of -$81,270,000, revealing a significant gap where operating expenses substantially exceeded total revenue. This negative net income is further compounded by an EBITDA of -$78,011,000, which suggests that core business operations are currently generating losses before financing and non-cash items. Free cash flow stands at -$42,980,752, indicating that the company is burning cash at a rate that must be covered by existing cash reserves or external financing to maintain liquidity. Margins across the board reflect this financial pressure, with a gross margin of 22.7% showing that production costs consume the majority of revenue, while an operating margin of -145.7% and a profit margin of -116.7% highlight severe inefficiencies or high investment costs relative to sales. The balance sheet shows a cash position of $239.95M against total debt of $44.01M, resulting in a debt-to-equity ratio of 16.85, which indicates a conservative leverage structure despite the lack of profitability. Additionally, the current ratio is 6.76, signaling strong short-term liquidity as current assets are more than six times current liabilities. Return on equity is -35.0% and return on assets is -18.2%, metrics that reveal management is currently destroying shareholder value and utilizing assets to generate negative returns rather than positive economic profit.
Valuation Assessment
Valuation metrics for Personalis present a complex picture given the company's unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -8.16. The negative forward P/E implies that the market is pricing in a future trajectory where earnings are expected to remain negative or that traditional earnings-based valuation methods are not applicable at this stage. The price-to-book ratio is 2.99, suggesting that the stock trades at a significant premium of nearly three times its book value, which may reflect investor confidence in intangible assets like intellectual property or future growth potential rather than current earnings. Alternative valuation multiples such as the price-to-sales ratio of 11.45 and an EV/EBITDA of -7.23 further illustrate that investors are valuing the company primarily on its revenue scale rather than profitability. The stock has traded between a 52-week high of $11.50 and a 52-week low of $2.83, with the current market capitalization implying a valuation that sits well above the 52-week low, indicating significant volatility and a wide trading range over the last year. The beta value of 2.11 indicates that the stock is highly volatile, moving with more than twice the magnitude of the broader market, which introduces substantial price risk for holders seeking stability.
Growth & Income
Revenue growth over the last year stands at 3.2%, while earnings growth is listed as N/A due to the company's persistent net losses. Since there are no positive earnings, the comparison between revenue and earnings growth is not applicable in a traditional sense, as the company is not yet generating the profits required to sustain positive earnings growth rates. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash and future earnings potential are theoretically reinvested into growth initiatives rather than distributed to shareholders. The overall growth and income profile is characterized by modest revenue expansion paired with significant cash burn and a complete absence of dividend income, positioning the company as a high-risk, high-revenue-growth play dependent on future profitability to sustain operations.